Andexanet alfa

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Recombinant antidote for the Factor Xa inhibitors rivaroxaban and apixaban, which was approved in the USA in May 2018 (AndexXa®).

Pharmacodynamics (Effect)This section has been translated automatically.

Andexanet alfa is able to cancel the effect of the Factor Xa inhibitors rivaroxaban (Xarelto®) and apixaban (Eliquis®) in an emergency. This provides an antidote for the Factor Xa inhibitors. The study is based on data from two Phase III studies (ANNEXA-R and ANNEXA-A) in which the safety and efficacy of reversing the effects of rivaroxaban and apixaban were tested in healthy volunteers.

Note(s)This section has been translated automatically.

The preparation Idarucizumab, which cancels out the effect of the thrombin inhibitor dabigatran (Praxdaxa®), has already been approved in Europe and the USA since 2015.

LiteratureThis section has been translated automatically.

  1. Siegal DM et al (2015) Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med. 2015 373:2413-1424.

Authors

Last updated on: 29.10.2020

Author: Prof. Dr. med. Peter Altmeyer